NCT07277231 2026-03-18
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 3 Recruiting
Clinical Trials
26 trialsNCT03336333 2026-03-09
SEQUOIA
BeOne Medicines
Phase 3 Active not recruiting
NCT06073821 2026-03-04
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
BeOne Medicines
Phase 3 Active not recruiting
NCT05650723 2026-02-25
Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT06637501 2026-02-23
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 2 Active not recruiting
NCT04282018 2026-02-20
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
BeOne Medicines
Phase 1/2 Completed
NCT07271667 2026-02-13
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Curis, Inc.
Phase 2 Recruiting
NCT04116437 2026-01-28
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
BeOne Medicines
Phase 2 Completed
NCT06697184 2025-12-17
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
BeOne Medicines
Phase 1/2 Active not recruiting
NCT07052695 2025-12-15
Mosunetuzumab for CLL MRD Clearance
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT06958705 2025-11-25
Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT04172246 2025-11-21
Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies
BeOne Medicines
Phase 1/2 Completed
NCT06839053 2025-11-19
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT05718869 2025-11-04
Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study
City of Hope Medical Center
Phase 2 Active not recruiting
NCT06849713 2025-09-25
BOSon
Massachusetts General Hospital
Phase 2 Recruiting
NCT03824483 2025-09-23
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05326308 2025-09-23
ARIADNE
iOMEDICO AG
Recruiting
NCT06859008 2025-08-05
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Recruiting
NCT07003464 2025-06-04
Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study
The First Hospital of Jilin University
Phase 2 Not yet recruiting
NCT03734016 2025-03-30
ALPINE
BeiGene
Phase 3 Completed
NCT03206918 2024-10-26
Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
BeiGene
Phase 2 Completed
NCT06544785 2024-10-24
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
PETHEMA Foundation
Phase 2 Recruiting
NCT06547944 2024-08-09
ZGR in TN CLL
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Active not recruiting
NCT06367374 2024-04-16
MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT02914938 2023-05-09
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
MEI Pharma, Inc.
Phase 1 Terminated
NCT05287984 2022-03-31
ZFCR/ZBR
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Unknown